Skip to main content
Premium Trial:

Request an Annual Quote

Genekor to Distribute Rosetta Genomics' Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has granted exclusive distribution rights in Greece for three of its assays to Genekor, an Athens-based molecular diagnostics firm.

The agreement covers Rosetta's miRview meso, which differentiates lung cancer from mesothelioma; miRview mets, which is designed to determine the source of cancers of unknown primary origin; and miRview squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

Kenneth Berlin, president and CEO of Rehovot, Israel-based Rosetta, noted that the alliance with Genekor is the firm's second distribution deal in Europe, and it plans to expand its distribution network to other European countries this year.

Last year, AXA Diagnostics inked a deal to serve as distributor of the tests in Italy.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.